Effect of Rifampin on the Pharmacokinetics of Ixabepilone in Patients With Advanced Cancer

R-Pharm

Status and phase: Completed; Phase 1

Conditions: Neoplasms; Advanced Solid Tumors

Treatments: Drug: ixabepilone; Drug: Rifampin

Study type: Interventional

Funder types: Industry

Identifiers

NCT00207090

CA163-102

Details and patient eligibility

About

The purpose of this study is to test how rifampin affects the removal of BMS-247550 (ixabepilone) from the body.

Enrollment: 19 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Up to three prior chemotherapy regimens
• Measurable or non-measurable disease
• Available for treatment and follow-up

Exclusion criteria

• Neuropathy
• Uncontrolled cardiovascular disease
• Refusal to participate in genetic analysis

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

19 participants in 1 patient group

Ixabepilone + rifampin

Experimental group

Treatment:

Drug: Rifampin

Drug: ixabepilone